However, optimal biomarkers for CTLA-4 inhibitors in NSCLC have not yet been determined and the biological effect of CTLA-4 blockade on T-regulatory cells is still a matter of debate,32 adding further complexity to the acquired resistance topic. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.